Epigenetix
Epigenetix Inc. is a biotech company focused on epigenetic drugs and precision targeting in cancer treatment. They are developing first-in-class oral drugs like EP31670 (NEO2734) for various cancers, including Myelofibrosis, prostate cancer, NUT carcinoma, pancreatic cancer, and breast cancer. The company collaborates with leading cancer centers and has a management team with extensive pharma and biotech experience. Their research includes clinical trials and a strong publication record in cancer research.
Industries
Nr. of Employees
small (1-50)
Products
Clinical-stage oral dual bromodomain/HAT inhibitor (epigenetic small molecule)
An oral, once-daily small-molecule inhibitor designed to target both bromodomain proteins and histone acetyltransferases for treatment of hematologic and solid tumors; advanced into clinical studies and being evaluated as monotherapy and in combination regimens.
Clinical-stage oral dual bromodomain/HAT inhibitor (epigenetic small molecule)
An oral, once-daily small-molecule inhibitor designed to target both bromodomain proteins and histone acetyltransferases for treatment of hematologic and solid tumors; advanced into clinical studies and being evaluated as monotherapy and in combination regimens.
Services
Collaborative execution of clinical studies with academic cancer centers and clinical investigators, including translational sample analysis and data sharing.
Collaborative execution of clinical studies with academic cancer centers and clinical investigators, including translational sample analysis and data sharing.
Expertise Areas
- Epigenetic drug discovery
- Oncology drug development
- Clinical trial management and site partnerships
- Regulatory submission (IND) and agency interactions
Key Technologies
- Dual-target epigenetic inhibition (bromodomain and HAT)
- Oral small-molecule medicinal chemistry
- Preclinical cancer models and patient-derived organoids
- Pharmacokinetic and pharmacodynamic assays
News & Updates
The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma
The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma